HitGen Inc. is a biopharmaceutical and contract research company that provides drug discovery services and technologies to the global pharmaceutical and biotechnology industry. It specializes in DNA-encoded library (DEL) technology, fragment-based drug discovery, structure-based drug design, and oligonucleotide-based therapeutics to discover novel small molecules and therapeutics for global clients and internal pipelines.
Subscribe to see HitGen Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
HitGen Inc. is a biotech company headquartered in China. Xcout tracks 1 named person at HitGen Inc., including SUIBO LI (董事).
A few of HitGen Inc.'s closest competitors — see the full list of competitors and alternatives →
WuXi Biology provides a comprehensive spectrum of preclinical biology services and solutions for drug discovery, supporting clients from target discovery and validation to hit finding, lead optimization, and candidate selection. The company offers specialized platforms and expertise across major disease areas and therapeutic modalities, including small molecules, oligonucleotides, peptides, and antibodies.
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
Selvita is an integrated contract research organization that provides comprehensive drug discovery and development services to the pharmaceutical and biotechnology industries. The company supports projects from target validation through preclinical candidate nomination and clinical trial batch manufacturing, specializing in small molecules, biologics, and agroscience under GMP and GLP standards.
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) providing services from drug discovery to manufacturing. It serves pharmaceutical and biotech companies by offering capabilities in synthetic medicinal chemistry, biology, drug metabolism and pharmacokinetics, process development, and drug substance manufacturing.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.